Arrowhead Pharmaceuticals (ARWR) Financial Statements & Analysis

Arrowhead Pharmaceuticals (ARWR) Income Statement

Arrowhead Pharmaceuticals reported revenue of $829.45M in fiscal 2025 (fiscal year ended Sep 30, 2025), up 23258.2% from $3.55M a year earlier. Arrowhead Pharmaceuticals posted a net loss of $1.63M, compared with a net loss of $599.49M a year earlier. Gross margin was 100.0% and operating margin 11.9%. In the most recent quarter, Q3 fiscal 2026 (ended Jun 30, 2026), revenue was $75.25M, up 171.0% from the same quarter a year earlier.

Arrowhead Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Arrowhead Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020	Sep 2019	Sep 2018	Sep 2017
Revenue & Gross Profit
Revenue	829.45	3.55	240.74	243.23	138.29	87.99	168.80	16.14	31.41
Cost of Revenue	0.00	18.60	12.49	10.42	0.00	0.00	0.00	0.00	0.00
Gross Profit	829.45	-15.04	228.24	243.23	138.29	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	592.60	505.87	353.19	297.31	201.88	123.54	76.63	48.30	46.25
Selling, General & Administrative	138.50	96.82	90.93	124.43	85.44	52.28	26.54	19.08	17.46
Operating Expenses	731.10	604.63	445.74	421.74	287.32	175.21	103.17	67.38	63.71
Operating Income	98.35	-601.08	-205.00	-178.51	-149.04	-93.16	61.19	-55.94	-37.00
Other Income/Expense
Interest Income	37.29	22.72	15.30	5.03	6.12	9.19	6.96	1.05	0.42
Interest Expense	-89.36	32.35	18.33	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	-46.81	-1.75	1.54	0.77	8.19	8.61	6.96	1.49	2.62
Income
Income Before Tax	51.53	-612.46	-206.49	-172.71	-140.85	-84.55	68.15	-54.45	-34.38
Income Tax Expense	21.42	-2.77	2.78	3.79	0.00	0.00	0.17	0.00	0.00
Net Income	-1.63	-599.49	-205.28	-176.06	-140.85	-84.55	67.98	-54.45	-34.38
Net Income - Continuous Operations	-1.63	-609.69	-209.28	-176.49	-140.85	-84.55	67.98	-54.45	-34.38
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	122.27	-561.51	-175.67	-162.29	-140.77	-87.22	65.63	-51.24	-32.31
EBIT	98.35	-580.11	-188.17	-172.71	-149.04	-	-	-	-
Depreciation & Amortization	23.93	1.94	1.62	1.61	8.27	5.94	4.44	4.70	4.69
Earnings Per Share
Basic EPS	-	-5.00	-2.00	-2.00	-1.00	-1.00	1.00	-1.00	-
Diluted EPS	-	-5.00	-2.00	-2.00	-1.00	-1.00	1.00	-1.00	-
Basic Shares Outstanding	133.76	119.78	107.31	105.96	103.75	100.72	93.86	83.64	73.15
Diluted Shares Outstanding	133.76	119.78	107.31	105.96	103.75	100.72	98.61	83.64	73.90

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Arrowhead Pharmaceuticals Financial Statements

What was Arrowhead Pharmaceuticals's revenue in fiscal 2025?

Arrowhead Pharmaceuticals reported revenue of $829.45M in fiscal 2025 (fiscal year ended Sep 30, 2025). That was up 23258.2% from $3.55M a year earlier.

Is Arrowhead Pharmaceuticals profitable?

No. Arrowhead Pharmaceuticals reported a net loss of $1.63M in fiscal 2025. In fiscal 2024 it lost $599.49M.

What is Arrowhead Pharmaceuticals's operating margin?

Arrowhead Pharmaceuticals's operating income was $98.35M on revenue of $829.45M in fiscal 2025, an operating margin of 11.9%, compared with -16927.1% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition